p27Kip1 and cyclin E expression and breast cancer survival after treatment with adjuvant chemotherapy

Journal of the National Cancer Institute

Volumn 98, Issue 23, 2006, Pages 1723-1731

  Porter, Peggy L ^a,b   Barlow, William E ^b,c   Yeh, I Tien ^d   Lin, Ming Gang ^a   Yuan, Xiaopu P ^a   Donato, Elizabeth ^a   Sledge, George W ^e   Shapiro, Charles L ^f   Ingle, James N ^g   Haskell, Charles M ^h   Albain, Kathy S ⁱ   Roberts, James M ^a   Livingston, Robert B ^b   Hayes, Daniel F ^j  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c SOUTHWEST ONCOLOGY GROUP STATISTICAL CENTER   (United States)

^d Mays Cancer Center at UT Health San Antonio   (United States)

^e INDIANA UNIVERSITY   (United States)

^f OHIO STATE UNIVERSITY   (United States)

^g MAYO CLINIC   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ LOYOLA UNIVERSITY CHICAGO   (United States)

^j UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CELL CYCLE PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLIN E; CYCLOPHOSPHAMIDE; DOXORUBICIN; ESTROGEN RECEPTOR; HORMONE RECEPTOR; PROGESTERONE RECEPTOR; STEROID RECEPTOR; TAMOXIFEN;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DOSAGE SCHEDULE COMPARISON; DRUG MEGADOSE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LOG RANK TEST; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MENOPAUSE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; TIME OF DEATH; TISSUE MICROARRAY; TUMOR VOLUME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CYCLIN E; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; SURVIVAL ANALYSIS;

EID: 33845640614     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djj467     Document Type: Article

References (48)

1. Clurman B, Roberts J. Cell cycle and cancer. J Natl Cancer Inst 1995;87:1499-501.
2. Pietenpol J, Bohlander S, Sato Y, Papadopoulos N, Liu B, Friedman C, et al. Assignment of the human p27Kip1 gene to 12p13 and its analysis in leukemias. Cancer Res 1995;55:1206-10.
3. Ponce-Castaneda MV, Lee MH, Latres E, Polyak K, Lacombe L, Montgomery K, et al. p27Kip1: Chromosomal mapping to 12p1212p13.1 and absence of mutations in human tumors. Cancer Res 1995;55:1211-4.
4. Konstantin S, Simpson J, Takeuchi S, Kawamata N, Miller C, Koeffler H. p27/Kip1 mutation found in breast cancer. Cancer Res 1996;56:2400-4.
5. Leach F, Ellredge S, Willson J, Markowitz S, Kinzler K, Vogelstein B. Amplification of cyclin genes in colorectal carcinomas. Cancer Res 1993;53:1986-9.
6. Keyomarsi K, O'Leary N, Molnar G, Lees E, Fingert HJ, Pardee AB. Cyclin E, a potential prognostic marker for breast cancer. Cancer Res 1994; 54:380-5.
7. Said T, Medina D. Cell cyclins and cyclin-dependent kinase activities in mouse mammary tumor development. Carcinogenesis 1995; 16:823-30.
8. Fero ML, Rivkin M, Tasch M, Porter P, Carow CE, Firpo E, et al. A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility in p27(Kip1)-deficient mice. Cell 1996;85:733-44.
9. Nourse J, Firpo E, Flanagan M, Coats S, Polyak C, Lee M, et al. Interleukin-2-mediated elimination of p27Kip1 cyclin-dependent kinase inhibitor prevented by rapamycin. Nature London 1994;372:570-3.
10. Coats S, Flannagan W, Nourse J, Roberts J. Requirement of p27Kip1 for restriction point control of the fibroblast cell cycle. Science 1996;272: 877-80.
11. Dulic V, Lees E, Reed S. Association of human cyclin E with a periodic G1-S phase protein kinase. Science 1992;257:1958-61.
12. Koff A, Cross F, Fisher A, Schumacher J, Leguellec K, Philippe M, et al. Human cyclin E, a new cyclin that interacts with two members of the CDC2 gene family. Cell 1991;66:1217-28.
13. Clurman B, Sheaff R, Thress K, Groudine M, Roberts J. Turnover of cyclin E by the ubiquitin-proteosome pathway is regulated by CDK2 binding and cyclin phosphorylation. Genes Dev 1996;10:1979-90.
14. Pagano M, Tam S, Theodoras A, Beer-Romero P, Del Sal G, Chau V, et al. Role of the ubiquitin-proteosome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 1995;269:682-5.
15. Tsihlias J, Kapusta LR, DeBoer G, Morava-Protzner I, Zbieranowski I, Bhattacharya N, et al. Loss of cyclin-dependent kinase inhibitor p27Kip1 is a novel prognostic factor in localized human prostate adenocarcinoma. Cancer Res 1998;58:542-8.
16. Tan P, Cady B, Wanner M, Worland P, Cukor B, Magi-Galluzzi C, et al. The cell cycle inhibitor p27 is an independent prognostic marker in small (T1a,b) invasive breast carcinomas. Cancer Res 1997;57:1259-63.
17. Singh SP, Lipman J, Goldman H, Ellis FH Jr, Aizenman L, Cangi MG, et al. Loss or altered subcellular localization of p27 in Barrett's associated adenocarcinoma. Cancer Res 1998;58:1730-5.
18. Porter PL, Malone KE, Heagerty PJ, Alexander GM, Gatti LA, Firpo EJ, et al. Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat Med 1997;3:222-5.
19. Catzavelos C, Bhattacharya N, Ung YC, Wilson JA, Roncari L, Sandhu C, et al. Decreased levels of the cell-cycle inhibitor p27Kip1 protein: prognostic implications in primary breast cancer. Nat Med 1997;3:227-30.
20. Keyomarsi K, Tucker S, Buchholz T, Callister M, Ding Y, Hortobagyi G, et al. Cyclin E and survival in patients with breast cancer. N Engl J Med 2002;347:1566-75.
21. Pohl G, Rudas M, Dietze O, Lax S, Markis E, Pirker R, et al. High p27Kip1 expression predicts superior relapse-free and overall survival for premenopausal women with early-stage breast cancer receiving adjuvant treatment with tamoxifen plus goserelin. J Clin Oncol 2003;21: 3594-600.
22. Spataro V, Litman H, Viale G, Maffini F, Masullo M, Golouh R, et al. Decreased immunoreactivity for p27 protein in patients with early-stage breast carcinoma is correlated with HER-2/neu overexpression and with benefit from one course of perioperative chemotherapy in patients with negative lymph node status: Results from International Breast Cancer Study Group Trial V. Cancer 2003;97:1591-600.
23. Le X-F, Pruefer F, Bast R. Her2-targeting antibodies modulate the cyclin-dependent kinase inhibitor p27 via multiple signaling pathways. Cell Cycle 2005;4:87-95.
24. Cariou S, Donovan J, Flanagan W, Milic A, Bhattacharya N, Slingerland J. Down-regulation of p21WAF1/CIP1 or p27Kip1 abrogates antiestrogen-mediated cell cycle arrest in human breast cancer cells. Proc Natl Acad Sci U S A 2000;97:9042-6.
25. Haskell C. Phase III comparison of adjuvant high-dose doxombicin plus cyclophosphamide AC versus sequential doxorubicin followed by cyclophosphamide A→C in breast cancer patients with 0-3 positive nodes (intergroup O137. Proc Am Soc Clin Oncol 2002;21:142.
26. Linden H, Haskell C, Green S, Osborne C, Sledge GJS, Shapiro CL, et al. Sequenced vs. simultaneous anthracycline and cyclophosphamide in high risk stage I-II breast cancer: Final analysis from INT-0137 (S9313). J Clin Oncol. In press 2006.
27. Ohtsubo M, Theodoras A, Schumacher J, Roberts J, Pagano M. Human cyclin E, a nuclear protein essential for the G1-to-S phase transition. Mol Cell Biol 1995;15:2612-24.
28. Barnes A, Pinder S, Bell J, Paish E, Wencyk P, Robertson J, et al. Expression of p27kip1 in breast cancer and its prognostic significance. J Pathol 2003;201:451-9.
29. Leivonen M, Nordling S, Lundin J, von Boguslawski K, Haglund C. p27 expression correlates with short-term, but not with long-term prognosis in breast cancer. Breast Cancer Res Treat 2001;67:15-22.
30. Tsuchiya A, Zhang G, Kanno M. Prognostic impact of cyclin-dependent kinase inhibitor p27kip1 in node-positive breast cancer. J Surg Oncol 1999;70:230-4.
31. Barbareschi M, van Tinteren H, Mauri F, Veronese S, Peterse H, Maisonneuve P, et al. p27kip1 expression in breast carcinomas: An immunohistochemical study on 512 patients with long-term follow-up. Int J Cancer 2000;89:236-41.
32. Wu J, Shen Z, Shao Z. Prognostic significance of cyclin-dependent kinase inhibitor p27kip1 expression in human breast cancer. Zhonghua Zhong Liu Za Zhi 1999;21:265-8.
33. Chappuis P, Donato E, Goffin J, Wong N, Begin L, Kapusta L, et al. Cyclin E expression in breast cancer: Predicting germline BRCA1 mutations, prognosis and response to treatment. Ann Oncol 2005;16:735-42.
34. Newman L, Xia W, Yang H, Sahin A, Bondy M, Lukmanji F, et al. Correlation of p27 protein expression with HER-2/neu expression in breast cancer. Mol Carcinog 2001;30:169-75.
35. Donovan J, Milic A, Slingerland J. Constitutive MEK/MAPK activation leads to p27(Kip1) deregulation and antiestrogen resistance in human breast cancer cells. J Biol Chem 2001;276:40888-95.
36. McCallum M, Baker C, Gillespie K, Cohen B, Stewart H, Leonard R, et al. A prognostic index for operable, node-negative breast cancer. Br J Cancer 2004;90:1933-41.
37. Thor AD, Berry DA, Budman DR, Muss HB, Kute T, Henderson IC, et al. erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Natl Cancer Inst 1998;90:1346-60.
38. Yamauchi H, Stearns V, Hayes D. The role of c-erbB-2 as a predictive factor in breast cancer. Breast Cancer 2001;8:171-83.
39. Dressler L, Berry D, Broadwater G, Cowan D, Cox K, Griffin S, et al. Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients. J Clin Oncol 2005;23:4287-97.
40. Berry D, Muss H, Thor A, Dressier L, Liu E, Broadwater G, et al. HER-2/ neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer. J Clin Oncol 2000;18: 3471-9.
41. Lane H, Beuvink I, Motoyama A, Daly J, Neve R, Hynes N. ErbB2 potentiates breast tumor proliferation through modulation of p27(Kip1)-Cdk2 complex formation: Receptor overexpression does not determine growth dependency. Mol Cell Biol 2000;20:3210-23.
42. Chu I, Blackwell K, Chen S, Slingerland J. The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer. Cancer Res 2005;65:18-25.
43. Spruck C, Won K, Reed S. Deregulated cyclin E induces chromosome instability. Nature 1999;401:297-300.
44. Loeb K, Kostner H, Firpo E, Norwood T, Tsuchiya K, Clurman B, et al. A mouse model for cyclin E-dependent genetic instability and tumorigenesis. Cancer Cell 2005;8:35-47.
45. Nielsen N, Arnerlov C, Emdin S, Landberg G. Cyclin E overexpression, a negative prognostic factor in breast cancer with strong correlation to oestrogen receptor status. Br J Cancer 1996;74:874-80.
46. Dutta A, Chandra R, Leiter LM, Lester S. Cyclins as markers of tumor proliferation: Immunocytochemical studies in breast cancer. Proc Natl Acad Sci U S A 1995;92:5386-90.
47. Rudolph P, Kuhling H, Alm P, Ferno M, Baldetorp B, Olsson H, et al. Differential prognostic impact of the cyclins E and B in premenopausal and postmenopausal women with lymph node-negative breast cancer. Int J Cancer 2003;105:674-80.
48. Akli S, Zheng P, Multani A, Wingate H, Pathak S, Zhang N, et al. Tumor-specific low molecular weight forms of cyclin E induce genomic instability and resistance to p21, p27, and antiestrogens in breast cancer. Cancer Res 2004;64:3198-208.